Drug Combination Details
| General Information of the Combination (ID: C36886) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Gefitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Phase 1 | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | MEK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | MEK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PSG1 | Molecule Info | |||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | H157 | CVCL_2458 | Mucosa squamous cell carcinoma | Homo sapiens | ||
| NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
| PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | |||
| In-vivo Model | H157 and H1299 cells (6*106 cells per mouse) were subcutaneously grafted into the right flanks of six-week-old female athymic nude BALBL/c mice. | |||||
| Experimental
Result(s) |
Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells. | |||||
